Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Daphne Day, Aaron R. Hansen

Research output: Contribution to journalReview ArticleResearchpeer-review

51 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown durable treatment responses in multiple tumor types by enhancing antitumor immunity. However, removal of self-tolerance can induce autoimmunity and produce a unique immune-driven toxicity profile, termed immune-related adverse events (irAEs). As ICIs gain approval for a growing number of indications, it is imperative clinicians increase their knowledge of and ability to manage irAEs. This review examines the etiology, presentation, kinetics, and treatment of irAEs and aims to provide practical guidance for clinicians.

Original languageEnglish
Pages (from-to)571-584
Number of pages14
JournalBioDrugs
Volume30
Issue number6
DOIs
Publication statusPublished - 1 Dec 2016
Externally publishedYes

Cite this